Truist Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $15
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Danielle Brill maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $50 to $15.
Truist Securities analyst Danielle Brill maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $50 to $15.